Paul Kelly

Biography

Paul Kelly has been actively involved as an analyst, consultant and investor in the biotechnology sector for the past twenty years. He began as an equity analyst at Mabon Securities in 1993, and later served in the same capacity at UBS Securities, Volpe, Brown, Whalen, ING Securities, and Merrill Lynch. Mr. Kelly was named to the inaugural Fortune Magazine All Star Analyst Team in 2000. Since 2007, Mr. Kelly has engaged in consulting for private and public biotechnology companies and for hedge funds. He currently manages his own investments and continues his industry consulting activities. Mr. Kelly holds an A.B. in biochemistry from Brown University, attended the University of Rochester School of Medicine, and received an M.B.A in finance from the William E. Simon School at the University of Rochester.

Research Interest

Paul Kelly has been actively involved as an analyst, consultant and investor in the biotechnology sector for the past twenty years. He began as an equity analyst at Mabon Securities in 1993, and later served in the same capacity at UBS Securities, Volpe, Brown, Whalen, ING Securities, and Merrill Lynch. Mr. Kelly was named to the inaugural Fortune Magazine All Star Analyst Team in 2000. Since 2007, Mr. Kelly has engaged in consulting for private and public biotechnology companies and for hedge funds. He currently manages his own investments and continues his industry consulting activities. Mr. Kelly holds an A.B. in biochemistry from Brown University, attended the University of Rochester School of Medicine, and received an M.B.A in finance from the William E. Simon School at the University of Rochester.